Equity Research, Broker Reports, and media content on Basilea Pharmaceutica

  • Access the latest forecasts, broker valuations, multiples, and video content from the city about Basilea Pharmaceutica
  • See live updates from analysts, company announcements, and other news in a personalised/single dashboard

Basilea Pharmaceutica

Company Profile

Research, Charts & Company Announcements

Research Tree provides access to ongoing research coverage, media content and regulatory news on Basilea Pharmaceutica. We currently have 40 research reports from 3 professional analysts.

  • Open: N/A
  • Range Today: N/A
  • 52 Week: 6740/9540c
  • Daily Volume: N/A
  • Daily Liquidity: 0.0%
  • # Shares: 0m
  • Market Cap: 819.1m
  • Latest PE (hist):
  • Div Yield:
Date Source Announcement
07Jan20 09:48 EQS Edison Investment Research Limited: Edison issues outlook on Basilea Pharmaceutica (BSLN)
23Apr19 11:27 EQS Basilea Pharmaceutica AG (BSLN-CH): Derazantinib has potential in iCCA and beyond
28Feb19 12:05 EQS Basilea Pharmaceutica AG (BSLN-CH): Cresemba on track, pipeline expanding
25Jan19 15:18 EQS Basilea Pharmaceutica AG (BSLN-CH): Derazantinib to enter combo trial with Roche's Tecentriq
10Jan19 15:37 EQS Basilea Pharmaceutica AG (BSLN-CH): Derazantinib interim data in line with expectations
10Dec18 06:15 GNW Basilea Pharmaceutica AG : Continued strong Cresemba® (isavuconazole) U.S. sales performance triggers CHF 10 million milestone payment to Basilea
14Nov18 06:15 GNW Basilea presents preclinical data on its anticancer drug candidate BAL101553 at EORTC-NCI-AACR symposium
  • Frequency of research reports


  • Research reports on

    Basilea Pharmaceutica

  • Providers covering

    Basilea Pharmaceutica